Evommune, Inc. - 8-K Filing
Evommune's Phase 2b trial for EVO756 in moderate-to-severe atopic dermatitis failed to meet primary endpoints, leading the company to halt AD development and shift focus to migraine prophylaxis. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $EVMN